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Abstract 
Objective 
Based on the role of the superior temporal gyrus (STG) in auditory processing, 
language comprehension and self-monitoring, this study aimed to investigate the 
relationship between STG cortical thickness and positive symptom severity in schizophrenia. 
 
Method 
This prospective meta-analysis includes data from 1,987 individuals with 
schizophrenia collected at seventeen centers around the world that contribute to the 
ENIGMA Schizophrenia Working Group. STG thickness measures were extracted from T1-
weighted brain scans using FreeSurfer. The study performed a meta-analysis of effect sizes 
across sites generated by a model predicting left or right STG thickness with a positive 
symptom severity score (harmonized SAPS or PANSS positive scores), while controlling for 
age, sex, and site. Secondary models investigated relationships between antipsychotic 
medication, duration of illness, overall illness severity, handedness and STG thickness.  
 
Results 
 Positive symptom severity was negatively related to STG thickness in both 
hemispheres (left: βstd=-0.052; p=0.021; right: βstd=-0.073; p=0.001) when statistically 
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controlling for age, sex and site. This effect remained stable in models including duration of 
illness, antipsychotic medication or handedness.  
 
Conclusion 
Our findings further underline the important role of the STG in hallmark symptoms in 
schizophrenia. These findings can assist in advancing insight into symptom-relevant 
pathophysiological mechanisms in schizophrenia.  
 
Keywords: schizophrenia, positive symptoms, superior temporal gyrus, cortical thickness, 
ENIGMA, FreeSurfer, MRI, SAPS, PANSS 
 
Significant Outcomes 
• Our work is based on data from the ENIGMA Schizophrenia Working group, a global 
alliance of scientists spread across many countries collectively analysing brain 
imaging data in schizophrenia. 
• Using a meta-analytical approach, we found that in schizophrenia positive symptoms 
were inversely related to cortical thickness in the superior temporal gyrus. 
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• Compared to previous studies, we were able to increase our sample size by a 
magnitude of 10 and to investigate potentially influencing, but small effects of age, 
gender, illness severity, and their complex interdependencies.  
Limitations 
• We followed a hypothesis-driven approach, as only effects in the superior temporal 
gyrus were studied. 
• We cannot address causal effects due the cross-sectional design of the current study.  
• We employed a measure of global positive symptom severity. It is however possible, 
that effects were driven by subdimension-specific features.  
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Introduction 
Schizophrenia is a heterogeneous disorder with a wide range of symptoms that vary 
over time and across patients. This large degree of variability hinders research on the 
underlying etiological factors and biological correlates. So, rather than investigating broad 
diagnostic categories, progress may also be made by studying distinct and continuous 
symptom dimensions of the disorder.  
Positive symptoms in schizophrenia refer to disturbances of thought and perception 
that are very uncommon in a healthy person and might lead to unusual behaviors. Hallmark 
features include hallucinations, delusions, and thought disturbances [1], which can cause 
substantial distress and disruption of functioning in patients. Premorbid signs of positive 
symptoms, including neuromotor abnormalities during childhood and adolescence, have 
been found to be a significant risk factor for the development of schizophrenia [2]. 
Furthermore, duration of untreated psychosis is one of the strongest predictor for poor 
functional outcome [3,4], and while antipsychotic treatment tends to reduce positive 
symptoms severity, 20 – 30% of patients do not respond to pharmacotherapy [5]. 
Investigating the brain-based correlates of positive symptoms (such as cortical thickness) 
may increase our understanding of symptom-related pathophysiological processes in 
schizophrenia. 
Cortical thickness deficits in patients with schizophrenia have been reported in a number 
of studies [6–8]. While deficits were observed across the entire cortex, temporal and frontal 
regions seemed to be most prominently affected [9–11]. Some studies suggest that deficits 
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in temporal regions are associated with poor cognitive functioning [12], while deficits in 
frontal regions are associated with more severe negative symptoms [13,14]. However, little 
is known about the link between cortical thickness and positive symptom severity in 
schizophrenia. 
The superior temporal gyrus (STG) includes key brain areas linked to auditory processing 
[15] and is part of a wider temporal-frontal-parietal network that is involved in language 
production, interpretation and self-monitoring [16,17]. Aberrant neural activity in the STG 
has been repeatedly associated with positive symptoms such as (mostly auditory) 
hallucinations and thought disturbances. A recent fMRI study [18] reported increased 
activity in the left medial planum temporale in patients with verbal auditory hallucinations, 
in line with findings from a related meta-analysis [19]. Another similar meta-analysis [20] 
differentiated between state- and trait-based studies (i.e. comparing periods of presence 
and absence of hallucinations within subjects vs comparing patients with hallucination to 
those without hallucination or to healthy controls). The authors observed converging 
evidence for the STG only in trait studies pointing to more permanent (and possibly 
structural) alteration in activity of the temporal cortex in hallucinating patients. In an fMRI 
study of verbal fluency, neural activity in bilateral superior temporal lobules was greater in 
patients with acute psychosis compared to patients in remission [21], further supporting the 
role of the STG in language disturbances and positive symptoms in schizophrenia. 
In addition to these functional findings, numerous MRI studies also reported deficits in 
STG structure in patients with schizophrenia. A meta-analysis of volumetric alterations in 
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schizophrenia found the left superior and medial temporal gyrus to be most consistently 
reduced in patients, although the link to symptoms was not investigated in that work [9]. 
Similar findings were reported in a volumetric meta-analysis [22], in which STG volume 
reductions were found to relate to various positive symptom dimensions such as 
hallucinations, thought disturbances and delusions. Related structural alterations such as 
cortical thinning and gray matter concentration reductions of the STG in patients have also 
been reported [10,11]. Interestingly, some studies investigated STG sub-regions and found 
that structural abnormalities in the STG of patients might be specific to the lateral aspect of 
the STG and the planum temporale, a region in which differences were even specific to 
patients with schizophrenia compared to those with bipolar disorder [23–25]. 
Building on the observed associations between neural activity and volume alterations in 
the STG [22] and aspects of positive symptoms, this study investigates the relationship 
between cortical thickness and positive symptoms. Few studies so far researched the link 
between STG thickness and positive symptoms. While non-significant correlations of 
thickness with positive symptoms have been reported in two small studies [26,27], a study 
by Padmanabhan et al. [28] observed that PANSS positive symptoms were negatively 
correlated with right temporal thinning, while Van Haren et al. [29] found a relationship 
between left STG cortical thinning and poor outcome (as measured through a factor score, 
which also included PANSS symptom ratings). 
 
Aims of the Study 
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Given the consistent link between positive symptoms and the STG based on functional 
and structural imaging studies, but divergent findings regarding the size of the effect (which 
might relate to sample size differences between studies and potentially moderating 
confounders such as illness severity, duration of illness, or antipsychotic medication), we set 
out to examine the effect size of the association between cortical thickness in the STG and 
positive symptoms in schizophrenia, using data from almost 2,000 individuals with 
schizophrenia pooled together  by the ENIGMA Schizophrenia Working Group. Analyses 
based on larger samples can help derive a more precise estimates of the underlying effect 
sizes and enable the examination of potential moderator effects. In light of prior structural 
imaging findings, we predicted that lower STG thickness was associated with higher positive 
symptom severity in schizophrenia. 
 
Material and Methods 
Study samples 
The current study includes a total of 1,987 individuals with schizophrenia from 
seventeen research groups around the world as part of the ENIGMA Schizophrenia Working 
Group. Schizophrenia diagnosis was based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM, editions III-R or IV) or the International Classification of Diseases 
(ICD, edition 10) criteria using either the Structured Clinical Interview for DSM Disorders 
(SCID), the Comprehensive Assessment of Symptoms and History (CASH), the Present State 
Examination (PSE), and/or a review of case files/medical records by trained clinicians. All 
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individuals had positive symptom ratings and structural imaging data available. Mean 
sample size at each research site was 117 patients (range: 23-245). See Supplementary 
Information (SI) Table 1 for more details. 
Each study sample was collected with participants’ written informed consent 
approved by local Institutional Review Boards. No individual subject imaging or clinical data 
were shared among the ENIGMA institutions. 
 
Positive symptom measures and score conversion 
Positive symptom severity was assessed using the Scale for the Assessment of Positive 
Symptoms (SAPS) [30] and the Positive and Negative Syndrome Scale (PANSS) [31]. Positive 
symptom scores were calculated as follows: 
1. Total SAPS (Composite) score = sum of SAPS items 1-6, 8-19, 21-24, and 26-33; 
2. Global SAPS (Summary) score = sum of SAPS items 7, 20, 25, and 34 (which include 
hallucinations, delusions, bizarre behaviour, and thought disorder global rating 
scores, respectively); or 
3. PANSS Positive = sum of PANSS items 1-7. 
To harmonize scores, we decided to convert all positive scores (i.e. PANSS Positive and 
Total SAPS Composite scores) to Global SAPS (Summary) scores following recommendations 
by Andreasen et al. [32] and using the algorithms published in van Erp et al. [33]. For 
additional details see SI Section 1.1. 
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Image acquisition and processing 
Based on i) well-replicated structural deficits in the STG in patients with 
schizophrenia, and ii) a link between functional and volumetric measures in the STG and 
positive symptom dimensions [9,19,22,28] we followed a region-of-interest (ROI) approach, 
focusing on cortical thickness in the STG. Left and right STG thickness values – based on the 
Desikan-Killiany atlas [34] - were obtained using FreeSurfer 
(http://surfer.nmr.mgh.harvard.edu) from high-resolution T1-weighted structural brain 
scans. Details on study type (single site or multisite), scanner vendor/strength/sequence, 
acquisition parameters and FreeSurfer versions used are provided in SI Table 2. For quality 
control, histograms of STG thickness values were generated and outliers were visually 
inspected by overlaying their parcellation on the subjects’ anatomical images. Only 
parcellations judged to be accurate upon visual inspection were subjected to statistical 
analyses (see SI Figure 1 for left and right STG thickness summarized by sample). 
 
Statistical analyses 
Within each sample, an association of positive symptoms with left and right STG 
thickness was analyzed using multiple linear regression analyses (R’s linear model function 
lm) predicting mean STG thickness by global SAPS score. The main analysis included age and 
sex as covariates. In cases of multi-site studies (FBIRN, MCIC, UMCU and Osaka) binary 
dummy covariates were included in the model to account for n−1 sites. For samples where 
information was available, secondary models were run separately with each of the following 
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covariates: 1) current antipsychotic medication (atypical/typical/both/none), 2) duration of 
illness, 3) illness severity (measured using PANSS Total score), and 4) handedness 
(right/left/ambidextrous). Analyses of individual subject data were performed by the site 
that contributed the sample, using code created within the ENIGMA collaboration. 
 
Meta-analyses 
From each sample, standardized regression coefficients were extracted from the 
main and secondary models as a measure of effect size for the left and right STG using the 
lm.beta function in the lm.beta R package [35]. A meta-analysis was conducted over these 
effect sizes using the rma function in the R package metafor [36]. We meta-analyzed the 
estimates across sites by weighting Fisher’s r-to-z transformed effect size values by sample 
size in a random-effects model using the default REML estimator. The same procedure was 
used to investigate the effects of age, sex, illness severity and duration of illness on STG 
thickness. For analyses, in which both left and right STG were analyzed, the significance 
threshold was corrected for two tests (p=0.05/2=0.025). 
Due to between-site differences in study characteristics such as antipsychotic 
medication, handedness and number of sites (single vs multi-site status; SI Table 1), we used 
moderator analyses to investigate between-sample differences. A moderator analysis was 
also used to investigate the potentially moderating effects of negative symptom severity on 
the association between positive symptoms and STG thickness. 
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Results 
Demographics 
Mean age (weighted by sample-size) across patient samples was 34 years (range: 28-
43). Patients were on average 68% male (range: 55-76%). The weighted mean duration of 
illness across the patient groups was 10 years (range: 1-20). For samples where current 
antipsychotic type and dose information was available, the weighted percentage of patients 
on first-generation (typical), second-generation antipsychotics (atypical), both typical and 
atypical or no antipsychotic medication was 11%, 71%, 9% and 9%. Ninety percent of 
patients were right-handed (range: 68-95), while only 8% (range: 4-14) were left-handed 
and 2% (range: 0-25) were ambidextrous (Table 1 and SI Table 1). 
 
Meta-analysis 
The weighted mean global SAPS scores across the samples was 5.91 (range: 3.19-
8.72). Weighted mean STG thickness was 2.69 mm (range: 2.41-2.85) in the left hemisphere 
and 2.74 mm (range: 2.41-2.88) in the right hemisphere. Meta-analytical results showed 
that global SAPS scores were negatively associated with left (βstd=-0.052; pSAPS=0.021; Figure 
1A) and right STG thickness (βstd=-0.073; pSAPS=0.001; Figure 1B) after accounting for age, sex 
and number of sites (if applicable) and after correcting for two tests. There was no 
indication of bias (Egger’s pleft=0.464 and pright=0.164; see SI Figure 2 for funnel plots) or 
effect size heterogeneity in either hemisphere (left: Q(16)=8.157; p=0.944; I2=0.00%; right: 
Q(16)=11.928; p=0.749; I2=0.00%).  For detailed results, see SI Table 3, models A and B). 
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Effects of covariates and moderator analyses 
We carried on investigating both within-sample and moderating between-sample 
effects of age, sex, illness severity and duration of illness, as well as antipsychotic 
medication, handedness and multi-site status based on samples in which this information 
was available (SI Table 1). 
While a meta-analysis of within-sample effects indicated that left and right STG 
thickness decreased with age (left: βstd=-0.357; p<0.0001; right: βstd=-0.332; p<0.0001), this 
did not differ between males and females (left: βstd=-0.030; p=0.202; right: βstd=-0.036; 
p=0.142). The main association of global SAPS and left/right STG thickness remained 
significant after controlling for age and sex (see main model above and SI Table 3, models A-
F).  
Overall illness severity was not associated with left or right STG thickness 
(pleft=0.131; pright=0.188; SI Table 3, models G and H) after accounting for age, sex and site (if 
applicable), but was positively correlated with global SAPS (weighted mean correlation = 
0.76; p<0.001). Additionally, accounting for illness severity within each sample also reduced 
the main effect of SAPS on left and right STG thickness (pSAPS-left=0.640; pSAPS-right=0.902; SI 
Table 3, models I and J), although multicollinearity might be a problem (weighted VIF = 2.26) 
as positive symptom severity is part of total symptom severity. 
Duration of illness (DOI) correlated negatively with left and right STG thickness (left: Fisher’s 
z=-0.267; p<0.001; right: Fisher’s z=-0.262; p<0.001) and positively with global SAPS score 
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(Fisher’s z=0.092; p=0.005) and age (Fisher’s z=0.834; p<0.001). However, DOI was not 
significantly associated with left or right STG thickness when age was included in the 
regression models (pDOI-left=0.424; pDOI-right=0.280; SI Table 3, models K and L), while the 
global SAPS effect in the same model remained significant (after multiple correction) in the 
right hemisphere (left: βstd=-0.052; pSAPS=0.038; right: βstd=-0.065; pSAPS=0.009; SI Table 3, 
models M and N). 
The main effect of SAPS on left and right STG thickness also remained significant, 
after additionally accounting for antipsychotic medication (left: βstd=-0.056; pSAPS=0.022; 
right: βstd=-0.063; pSAPS=0.011; SI Table 3, models O and P), handedness (left: βstd=-0.055; 
pSAPS=0.019; right: βstd=-0.075; pSAPS=0.001; SI Table 3, models Q and R), or negative 
symptom severity (left: βstd=-0.053; pSAPS=0.022; right: βstd=-0.073; pSAPS=0.001; SI Table 3, 
models W and X), which themselves did not moderate the global SAPS – STG thickness 
relationship between samples (left: pMED=0.734; pHAND=0.727; pSANS=0.871; right: pMED=0.735; 
pHAND=0.576; pSANS=0.946; SI Table 3, models S - X).  
 
Discussion 
Summary 
 The main finding of this study is that positive symptom severity, but not total 
symptom severity, is negatively associated with STG cortical thickness in schizophrenia. This 
finding is present in both hemispheres without indication of effect size heterogeneity. The 
finding remained stable after accounting for duration of illness, age, sex, and antipsychotic 
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medication. This investigation has two major strengths. First, by conducting a meta-
analytical approach within the ENIGMA consortium this study’s sample size is 10 times 
greater than that of prior studies investigating the relationship between STG and positive 
symptoms. Second, the large sample size allowed the investigation of the potentially 
confounding effects of age, sex, illness severity, duration of illness, antipsychotic 
medication, and handedness on the relationship between STG thickness and positive 
symptom severity.  
 
Cortical thickness in the superior temporal gyrus and positive symptoms 
 We found a negative correlation between positive symptoms and cortical thickness 
in the STG, which corroborates findings of previous studies [28,29,37]. Van Haren et al. [29] 
reported a link between STG thickness and poor functional and symptomatic outcome in a 
sample of 96 patients.  Of note, their outcome variable was based on PANSS symptom 
ratings and other measures of global functioning and hence indexes a somewhat broader 
range of schizophrenia symptoms. Padmanabhan et al. [28] investigated directly PANSS 
positive symptoms effect on STG thickness in a cohort of 455 patients with schizophrenia, 
schizoaffective or bipolar disorder. The authors reported an inverse relationship between 
positive symptoms and temporal thinning, with strongest effects in the schizophrenia 
subgroup. Importantly, the samples in both studies included chronic patients with a mean 
duration of illness of 11 and 19 years, respectively. Therefore, it remains unclear whether 
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effects also apply to first-episode patients or might be confounded by factors such as 
prolonged medication intake (although no correlation between poor functional and 
symptomatic outcome and medication intake was evident in van Haren et al. [29]). 
Strikingly, the majority of studies, which failed to identify an association between STG 
thickness and positive symptoms, were based on young, largely unmedicated, first-episode 
patients [38–40]. Two investigations, which did not find a correlation between positive 
symptom scores and thickness in the temporal (or any other cortical) regions, studied 
minimally medicated or medication-naïve, first-episode patients with a duration of illness 
less than one year [39,41]. Similarly, two more studies, which compared patients with a 
psychotic disorder versus high-risk or healthy control participants and failed to find 
differences in STG thickness, were based on young (mean age range across studies 21 – 24 
years), first-episode patients [38,40]. 
In our study, duration of illness related negatively to STG thickness and positively to global 
SAPS scores, but we could not identify duration of illness effects beyond age effects. 
Reassuringly, the fact that i) the association between STG thickness and positive symptoms 
remained stable after accounting for age effects, and ii) we did not find moderating effects 
of antipsychotic medication indicate that these are more etiological effects rather than 
secondary effects of due to contextual correlates of the disease status. In support, STG 
thinning was also observed in a smaller study by Ziermans et al. [37] in ultra-high risk 
participants, who later became psychotic, compared to healthy controls, indicating that STG 
thinning might precede disease onset and possibly medication or other downstream effects. 
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Similar results were reported by Oertel-Knöchel et al. [27], who linked STG thinning to a 
predisposition towards hallucinations (but not to PANSS positive symptom scores itself) in 
patients and unaffected relatives, but not in controls. As put forward by the authors, this 
points towards a possible trait-like STG-symptom link – an argument, which is also 
supported by findings in Kühn and Gallinat’s meta-analysis [20]. 
Studies based on patients with neurological (but not psychiatric) disorders found the 
STG to be involved in auditory processing [15] and – in conjunction with a wider temporal-
frontal-parietal network – to have a role in language production, interpretation and self-
monitoring [16,17]. Interestingly, psychosis-like symptoms such as illusions and 
hallucinations, have long been observed during electrical stimulation of the STG and in 
patients with epilepsy (for a review see [42]). Moreover, a recent meta-analysis found that 
repetitive transcranial magnetic stimulation applied to temporoparietal areas is an effective 
treatment of auditory verbal hallucinations [43]. These studies further support our own 
findings that the STG appears to be a central region involved in processes underlying 
positive symptoms and is less affected by confounders that are highly prevalent in 
schizophrenia patients. 
 
Potential modulators 
Illness severity was the only significant modulator observed on the current study, as 
positive symptoms no longer predicted STG thickness after accounting for illness severity (as 
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well as age and sex). While this may indicate that some of the variance in thickness that is 
explained by positive symptoms may also depend on illness severity, we would also like to 
emphasize that it is conceptually and statistically challenging to disentangle the effects of 
illness severity and positive symptoms as they were highly correlated. Illness severity was 
not linked to STG thickness in two prior studies [11,44]. This divergence in findings may be 
due in part to different sample characteristics. 
 
Limitations 
The following limitations should be considered when interpreting our findings. First, 
we followed a hypothesis-driven approach, as only effects in the superior temporal gyrus 
were studied. Second, we cannot address directional effects due the cross-sectional design 
of the current study. Longitudinal, prospective studies should determine whether positive 
symptoms precede or follow the development of cortical thinning. Third, we employed a 
measure of global positive symptom severity and of global STG thickness. It is however 
possible, that effects were driven by either symptom sub-dimensions or STG sub-region 
specific features. Fourth, while we discovered no effect of current antipsychotic medication, 
it is still possible that cumulative medication use (i.e. taking into account the treatment 
duration) may have important confounding effects on brain structure [45]. 
 
Conclusion 
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 We used data from several large cohorts from three continents collected within the 
ENIGMA consortium comprising almost 2,000 patients to study the association between 
cortical thickness in the superior temporal gyrus and positive symptoms. Positive symptom 
severity was significantly related to thickness in this region in both hemispheres, and 
remained stable after accounting for age, sex, antipsychotic medication and duration of 
illness. Illness severity had some modulating effects. These results may help to advance 
insight into symptom-relevant pathophysiological mechanisms in schizophrenia.  
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Tables and Figures 
  estimate range data available for N 
number of studies 
% males 68 55-76 17 
Mean age in years 34 28-43 17 
Mean SAPS Global 5.91 3.19-8.72 17 
Mean duration of illness in years 10 1-20 13 
Mean illness severity (PANSS Total) 70.44 49.81-
90.22 
11 
Antipsychotic medication   13 
    %Atypical 71 39-91  
    %Typical 11 0-45  
    %Both A & T 9 0-24  
    %None 9 0-53   
Handedness   14 
    %Right 90 68-95  
    %Left 8 2-14  
    %Ambidextrous 2 0-25   
Cortical thickness   17 
    Mean left superior temporal 
gyrus  
2.69 2.41-2.85  
    Mean right superior temporal 
gyrus  
2.74 2.41-2.88  
 
Table 1. Demographics. Mean are weighted by study sample size. 
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Figure 1. Forest plot of association between global SAPS and cortical thickness in the A) left 
and B) right superior temporal gyrus across all 17 study sites, controlling for age, sex and 
number of sites (if applicable). Fisher’s transformed standardized regression coefficients are 
denoted by black boxes. Black lines indicate 95% confidence intervals. The combined 
estimate for all sites is represented by a black diamond with the outer edges of the diamond 
indicating the confidence interval limits. 
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Supplementary Materials 
 
SM 1 Method 
 
SM 1.1 Symptom score conversion algorithms 
 
Global SAPS (Summary) Score = -3.222 + (0.567*PANSS Positive score) 
Global SAPS (Summary) Score = 2.3526 + (0.1932*Total SAPS (composite) score) 
 
SM 1.2 Imaging descriptives 
 
Walton et al. ENIGMA-SZ: positive symptoms 
36 
 
 
 
SM Figure 1s. Left (A-B) and right (C-D) superior temporal gyrus cortical thickness descriptives 
(min/mean/sd/max) by study site. 
SM 2 Results 
 
SM 2.1 Funnel plots for main models 
 
In the main model we investigated the effect of global SAPS scores on left or right STG thickness, 
covarying for gender, age and the number of sites as dummy variables (where applicable). Shown 
below are the funnel plots for the meta-analytical standardized regression beta of the global SAPS 
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score on a) left or b) right STG thickness. Results were based on estimates from 17 studies using a 
restricted maximum likelihood (REML) approach.  
 
 
 
SM Figure 2s. Funnel plots. Individual study regression coefficients for A) left and B) right STG are 
plotted against sample variance (a measure of the precision of the data).  
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